



Balance Therapeutics | BT-D-001 IH202 | €-R0E-G€FJ

Dear Patient,

You may qualify for a clinical research study called Arise² that is enrolling now.

The purpose of the Arise² study is to look at the safety and effectiveness of an investigational drug (BT-D-001) on mental fogginess, sleep, functionality, and quality of life in those with IH. Currently, there are no approved treatments for IH. The study drug is considered “investigational” treatment because it has not been approved by regulatory authorities like the US Food and Drug Administration (FDA) for treatment IH.

If you are eligible and decide to join the Arise² study, you will take the study drug for 14 days. You will also take the placebo (no active ingredients) for 14 days. There will be a 14-day washout period between these two treatment periods, meaning you will not take any study medication during this time. A study staff experienced in clinical trials will monitor your health throughout the study.

If you are currently taking a stimulant, you may be able to stay on your stimulant while in the study under certain conditions.

You will receive at no cost:

- Both study drug and placebo
- All study-related tests
- Compensation for time and travel

What we learn from the Arise² study may help find effective treatment options for those with IH.

To receive additional information about the Arise² study, or if you know someone who may be interested, visit www.arise2study.com or contact my office as soon as possible.

Sincerely,

V@ Arise² Ústudy V^æ

Ò{ æKCEà^GO àææ) & E@!æ ^ çæ B{ {

Ú@ }^æí €í FÉ ïïÁ

Á

